ERBB2 and aneurysmal bone cyst: In the other subgroups, the two dual-target regimens also displayed curative effects, without significant differences.<h4>Discussion</h4>Overall, the results of the current study suggested that HPyr could be equivalently used as HP, as a first-line treatment strategy for patients with HER2-positive ABC.